CompletedInterventionalPhase 3Updated May 30, 2011
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | NCT00332384 | Trialant
CompletedInterventionalPhase 3Updated May 30, 2011
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT00332384
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
573Actual
Last Update Posted
May 30, 2011Estimated
Start Date
Jan 2000
Primary Completion Date
Nov 2001Actual
Completion Date
Nov 2001Actual
Brief Summary
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Ocular Hypertension
brimonidine/timolol fixed combination
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes
Patient requires IOP-lowering drug in both eyes
Exclusion Criteria:
Uncontrolled medical conditions
contraindication to beta-adrenoceptor antagonist or brimonidine therapy